Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

Summary

The purpose of the study was to assess preliminary efficacy, safety, and tolerability of LYS006 in adult patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further development in this indication.

Timeline

Start

2020-02-03

Primary completion

2022-11-07

Completion

2022-11-07

Outcome

Missed primary endpoint

Stopped (Business): “Sponsor decision due to strategic considerations”

registry analysis (other test); LYS006 20mg vs Placebo; p = 0.314; Posterior estimate treatment difference -3.29 (90% CI -18.02 to 13.23) NCT04074590 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LYS006	Unknown	—	Oral

Indications